ArticleIranian journal of basic medical sciences2017
The miR-383-LDHA axis regulates cell proliferation, invasion and glycolysis in hepatocellular cancer.
Article in Iranian journal of basic medical sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Lactate and lactylation in hepatocellular carcinoma: A new frontier in metabolic-epigenetic interactions.Medical oncology (Northwood, London, England) · 2026Review
- Beyond the convergence of metabolic reprogramming in primary liver cancer: a comprehensive review on energy and lipids metabolism.Frontiers in cell and developmental biology · 2026Review
- MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.Molecular biology reports · 2024Article
- Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.European journal of medical research · 2023Article
- MicroRNAs as Regulators of Cancer Cell Energy Metabolism.Journal of personalized medicine · 2022Review
- A Concise Review of MicroRNA-383: Exploring the Insights of Its Function in Tumorigenesis.Journal of Cancer · 2022Review
- MicroRNA-383: A tumor suppressor miRNA in human cancer.Frontiers in cell and developmental biology · 2022Review
- Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma.Frontiers in oncology · 2022Review
- Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma.Cancer medicine · 2021Article
- HyperpolarizedScientific reports · 2021Article
- Long Non-Coding RNAs: Role in Testicular Cancers.Frontiers in oncology · 2021Review
- The Heterogeneity of Liver Cancer Metabolism.Advances in experimental medicine and biology · 2021Article
- Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- MicroRNA-383 inhibits proliferation, migration, and invasion in hepatocellular carcinoma cells by targeting PHF8.Molecular genetics & genomic medicine · 2020Article
- Inhibition of miR-383 suppresses oxidative stress and improves endothelial function by increasing sirtuin 1.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Article
- MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer.Cancer biomarkers : section A of Disease markers · 2020Article
- Non-coding RNAs: emerging regulators of glucose metabolism in hepatocellular carcinoma.American journal of cancer research · 2020Review
- MicroRNA-383 inhibits doxorubicin resistance in hepatocellular carcinoma by targeting eukaryotic translation initiation factor 5A2.Journal of cellular and molecular medicine · 2019Article
- Article
- Identification and functional characterization of Lys-trimethylation of lactate dehydrogenase A.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the correlation between expression patterns and functions of miR-383 and LDHA in hepatocellular cancer (HCC). MATERIALS AND
methodsWe detected the expression of miR-383 and LDHA in 30 HCC tissues and their matched adjacent normal tissues using qRT-PCR. Then we performed MTT assay, foci formation assay, transwell migration assay, glucose uptake assay and lactate production assay to explore the function of miR-383 in cell proliferation, invasion and glycolysis in HCC cell lines. Luciferase reporter assay was used to explore whether LDHA was a target gene of miR-383. Western blot and qRT-PCR were used to further confirm LDHA was targeted by miR-383. Then the above functional experiments were repeated to see whether the function of LDHA could be inhibited by miR-383.
resultsThe results of qRT-PCR showed that miR-383 was down-regulated in HCC tissues compared with their matched adjacent normal tissues. Functional experiments showed that overexpression of miR-383 significantly suppressed cell proliferation, invasion and glycolysis. Luciferase reporter assay showed LDHA was a target gene of miR-383 and expression of LDHA was inversely correlated with that of miR-383 in HCC. Besides, increased cell proliferation, invasion and glycolysis triggered by LDHA could be inhibited by overexpression of miR-383 in HCC cell lines.
conclusionOur study proved that miR-383 is down-regulated in HCC and acts as a tumor suppressor through targeting LDHA. Targeting the miR-383-LDHA axis might be a promising strategy in HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.